MedTrace Logo

Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care

NCT01163916 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 252

Last updated 2012-12-07

Study results available
· View outcomes & findings →

Summary

The primary objective of this post-marketing observational study was to obtain data on the characteristics (patient age/gender; disease type, severity and duration; disease specific treatment history; current concomitant medications; other relevant medical history) of patients prescribed adalimumab (Humira®) for rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) as part of routine clinical care in Russia.

Conditions

Sponsors & Collaborators

  • Scientific Research Institute of Rheumatology, Moscow

    collaborator UNKNOWN

  • Almedis

    collaborator INDUSTRY

  • Abbott

    lead INDUSTRY

Principal Investigators

  • Andrey N Strugovschikov, MD · Abbott Russia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01163916 on ClinicalTrials.gov